Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Merck loses ground to Summit
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(897)
•••
Comment by CancerSlayeron Sep 09, 2024 5:04pm
167 Views
Post# 36215516

RE:Merck loses ground to Summit

RE:Merck loses ground to Summit
Longholder99 wrote: Competition in the lung cancer arena has Summit Therapeutics Ivonescimab outperforming Keytruda in NSCLC.   Gee.....if I was the Merck Board and I was reading all this discussion about Ruvidar (since Merck is manufacturing it) and my stock price just dropped on this news.  What would I do about it?  


Still a ways to go for Summit, but its new drug signifies there will be a growing number of/bigger bumps in the road for Merck USA.  Keytruda will face increasingly more pressure in coming years (& hopefully we have a lot to do with that pressure), not to mention the drug goes off patent in 2028, which in itself will significantly impact sales for Merck...to the likely tune of mult. $billions.  Merck should be doing everything it can to reduce its reliance on Keytruda, especially considering there will be more newer/more effective treatments coming to market shortly...depending on how one defines shortly
; ).  JMO.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities